This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor.—Experienced physicians may be unenthusiastic about the Fifth Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) recommendations for treatment of hypertension for reasons not addressed by Drs Siegel and Lopez.¹ -Blockers significantly impair quality of life for many patients. For instance, if a husband neglects to mention his drug-related impotence to a physician, his wife might do so. Lethargy, constipation, and bronchospasm are common enough adverse effects to engender reluctance among physicians to burden patients with -blockers. Except for dry cough in some patients, angiotensin-converting enzyme inhibitors are remarkably free of adverse effects, and, in addition to their antihypertensive actions, may improve left ventricular function and may reduce the risk and severity of diabetic nephropathy.²

The use of combined hydrochlorothiazide with triamterene preparations reduces the need for potassium supplementation and for frequent electrolyte measurements. Costs of laboratory tests and potassium . . . [Full Text of this Article]

David Siegel, MD, MPH; Julio Lopez, PharmD
Department of Veterans Affairs
Northern California Health Care System
Martinez

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Trends in Antihypertensive Drug Use in the United States: Do the JNC V Recommendations Affect Prescribing?
David Siegel and Julio Lopez
JAMA. 1997;278(21):1745-1748.
ABSTRACT